Table 5.
Imaging Features | Malignant Lesions | Benign Lesions | Total (n = 104) |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC (n = 64) |
Metastasis (n = 9) | ICC (n = 6) |
Lymphoma (n = 1) | Hemangioma (n = 10) | FNH (n = 7) |
DN (n = 3) |
AML (n = 1) |
Adrenal Rest Tumor (n = 1) | Focal Fatty Area (n = 1) | Focal Spared Lesion (n = 1) | ||
Gray-scale echogenicity | ||||||||||||
Hyperechoic | 13 | 3 | 1 | 0 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 25 |
Isoechoic | 10 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 13 |
Hypoechoic | 41 | 5 | 5 | 1 | 7 | 3 | 2 | 1 | 0 | 0 | 1 | 66 |
Arterial phase | ||||||||||||
Hyperenhancement | 56 | 2 | 5 | 1 | 7 | 7 | 1 | 1 | 1 | 0 | 0 | 81 |
Diffuse | 56 | 2 | 4 | 1 | 4 | 7 | 1 | 1 | 1 | 0 | 0 | 77 |
Rim | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Peripheral nodular | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Iso-enhancement | 7 | 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 14 |
Hypo-enhancement | 1 | 3 | 1 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 9 |
Kupffer phase | ||||||||||||
Isoechoic | 11 | 0 | 0 | 0 | 7 | 5 | 3 | 1 | 0 | 1 | 1 | 29 |
Hypoechoic | 53 | 9 | 6 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 73 |
Marked | 16 | 9 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 |
Mild | 37 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 41 |
Hyperechoic | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
Washout | ||||||||||||
<60 s | 6 | 9 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 |
HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; FNH, focal nodular hyperplasia; DN, dysplastic nodule; AML, angiomyolipoma.